Use of bacteria as anticancer agents

Bibliography

• HEPPNER F, MOSE JR The liquefaction (oncolysis) ofmalignant gliomas by a non pathogenic Clostridium. Acta Neurochir. (Wien) (1978) 42:123–125.
   PubMed Web of Science ®Google Scholar
• PAWELEK JM, LOW KB, BERMUDES D: Tumour targeted Salmonella as a novel anticancer vector. Cancer Res. (1997) 57:4537–4544.
   PubMed Web of Science ®Google Scholar
• •• First description of tumour targeted Salmonella forming thebasis to TAPET therapy.
   Google Scholar
• LOW KB, ITTENSOHN M, LE T et al.: Lipid-A mutant Salmonella with suppressed virulence and TNFa induction retain tumour-targeting in vivo. Nature Biotech. (1998) 17:37–41.
   Web of Science ®Google Scholar
• PLATT J, SODI S, KELLEY M et al.: Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur. J. Cancer (2000) 36:2397–2402.
   PubMed Web of Science ®Google Scholar
• BERMUDES D, LOW B, PAWELEK J: Tumor-targeted Salmonella. Highly selective delivery vectors. Adv. Exp. Med. Biol. (2000) 465:57–63.
   PubMed Web of Science ®Google Scholar
• •• Excellent review of tumour targeting using Salmonella.
   Google Scholar
• PASTAN I, KREITMAN RJ: Immunotoxins for targeted cancer therapy. Adv. Drug Deliv. Rev. (1998) 31:53–88.
   PubMed Web of Science ®Google Scholar
• •• Excellent review of immunotoxins for cancer therapy.
   Google Scholar
• ARAB S, RUTKA J, LINGWOOD C: Verotoxin induces apoptosis and the complete, rapid, long-term elimina-tion of human astrocytoma xenografts in nude mice. Oncol. Res. (1999) 11:33–39.
   PubMed Web of Science ®Google Scholar
• LINGWOOD CA: Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineo-plasia. Biosci. Rep. (1999) 19:345–354.
   PubMed Web of Science ®Google Scholar
• LACASSE EC, SALEH MT, PATTERSON B et al.: Shiga-like toxin purges human lymphoma from bone marrow of severe combined irnmunodeficient mice. Blood (1996) 88:1561–1567.
   PubMed Web of Science ®Google Scholar
• LACASSE EC, BRAY MR, PATTERSON B et al.: Shiga-liketoxin-1 receptor on human breast cancer, lymphoma and myeloma and absence from CD34(+) hemato-poietic stem cells: implications for ex vivo tumour purging and autologous stem cell transplantation. Blood (1999) 94:2901–2910.
   PubMed Web of Science ®Google Scholar
• ARBUS GS, GRISARU S, SEGAL 0 et al.: Verotoxin targetslymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leuk. Res. (2000) 24:857–864.
   Google Scholar
• NOAKES KL, TEISSERENC HT, LORD JM et al.: Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. FEBS Lett. (1999) 453:95–99.
   PubMed Web of Science ®Google Scholar
• HAICHEUR N, BISMUTH E, BOSSET S et al.: The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow AMC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. (2000) 165:3301–3308.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MR, HEIMBROOK DC, RUSSO P eta/.: Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res. (1995) 1:57–61.
   Google Scholar
• ZHANG M, ZHAO X, LI H et al.: Cloning and expression of the gene coding for IL-2(60)-PE40, a molecular targeted protein. Chin. Med. Sci. J. (1995) 10:136–140.
   PubMedGoogle Scholar
• KREITMAN RJ, PASTAN I: Targeted toxin hybrid therapy. In: Novel therapeutics from Modern Biotech-nology. Oxender DL, Post LE, Springer, Berlin (1999).
   Google Scholar
• LASKE DW, YOULE RJ, OLDFIELD EH: Tumour regres-sion with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumours. Nat. Med. (1997) 3:1362–1368.
   PubMed Web of Science ®Google Scholar
• PURI RK: Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Toxicol. Pathol. (1999) 27:53–57.
   PubMed Web of Science ®Google Scholar
• •
   Google Scholar
• HUECK CJ: Type HI protein secretion systems in bacterial pathogens of animals and plants. Microbiol. Mol. Biol. Rev. (1998) 62:379–433.
   PubMed Web of Science ®Google Scholar
• BLEVES S, CORNELIS GR: How to survive in the host: the yersinia lesson. Microbes Infect. (2000) 2:1451–60.
   PubMed Web of Science ®Google Scholar
• •• Excellent review of Yersinia Type III secretion system as abackground for the potential use of these organisms for cancer therapy.
   Google Scholar
• GALAN JE, COLLMER A: Type BI secretion machines: bacterial devices for protein delivery into host cells. Science (1999) 284:1322–1328.
   PubMed Web of Science ®Google Scholar
• •• Excellent review of Type II secretion system as a method ofprotein delivery into cells.
   Google Scholar
• BOYD AP, GROSDENT N, TOTEMEYER S et al.: Yersinia enterocolitica can deliver Yop proteins into a wide range of cell types: development of a delivery system for heterologous proteins. Eur. J. Cell. Biol. (2000) 79:659–671.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Textbook of Gene Therapy. Hogrefe & Huber,Seattle-Gottingen-Bern (1998).
   Google Scholar
• KERR DJ, YOUNG LS, SEARLE PF et al.: Gene directed enzyme prodrug therapy for cancer. Adv. Drug Deliv. Rev. (1997) 26:173–184.
   PubMed Web of Science ®Google Scholar
• •• Excellent review of GDEP therapy for cancer.
   Google Scholar
• TRINH QT, AUSTIN EA, MURRAY DM et al.: Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme prodrug systems in a human colorectal carcinoma cell line. Cancer Research (1995) 55:4808–4812.
   PubMed Web of Science ®Google Scholar
• ROGULSKI KR, KIM JH, KIM SH et al.: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. (1997) 8:73–85.
   PubMed Web of Science ®Google Scholar
• PARKER WB, KING SA, ALLAN PW et al. in vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther. (1997) 8:1637–1644.
   PubMed Web of Science ®Google Scholar
• •• Excellent example of use of a bacteria for gene therapy.
   Google Scholar
• BAILEY SM, KNOX RJ, HOBBS SM et al.: Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy. Gene Ther. (1996) 3:1143–1150.
   Google Scholar
• •• Review of suicide gene therapy.
   Google Scholar
• LEMMON MJ, VAN ZIJL P, FOX ME et al.: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. (1997) 4:791–796.
   PubMed Web of Science ®Google Scholar
• TAMIYA T, ONO Y, WEI MX et al Escbericbia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. (1996) 3:155–162.
   PubMed Web of Science ®Google Scholar
• PAULUS W, BAUR I, OBERER DM, BREAKEFIELD XO, REEVES SA: Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. J. Neurosurg. (1997) 87:89–95.
   PubMed Web of Science ®Google Scholar
• KUNITOMI M, TAKAYAMA E, SUZUKI S et al.: Selectiveinhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene. Jpn. J. Cancer Res. (2000) 91:343–350.
   PubMedGoogle Scholar
• JAIN KK: Emerging therapeutic targets for glioblas-toma multiforrne. Emerging Therapeutic Targets (1999) 3(4):613–627.
   Google Scholar